Zimmer Biomet (NYSE:ZBH) Given New $138.00 Price Target at Stifel Nicolaus

Zimmer Biomet (NYSE:ZBH) had its target price raised by equities research analysts at Stifel Nicolaus from $130.00 to $138.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 25.24% from the stock’s current price.

Several other equities research analysts also recently weighed in on ZBH. Truist Financial upped their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Finally, Raymond James lowered their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Stock Up 0.4 %

Shares of ZBH traded up $0.47 during midday trading on Thursday, reaching $110.19. 247,267 shares of the company were exchanged, compared to its average volume of 1,662,816. The company has a market cap of $21.94 billion, a price-to-earnings ratio of 20.95, a P/E/G ratio of 1.89 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 1-year low of $100.67 and a 1-year high of $133.90. The stock has a 50-day moving average price of $107.85 and a 200-day moving average price of $108.07.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the firm posted $1.65 EPS. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. Research analysts expect that Zimmer Biomet will post 7.99 earnings per share for the current year.

Institutional Investors Weigh In On Zimmer Biomet

Large investors have recently made changes to their positions in the stock. BLB&B Advisors LLC grew its stake in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after buying an additional 100 shares during the last quarter. CKW Financial Group grew its position in shares of Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. FWG Holdings LLC lifted its holdings in Zimmer Biomet by 2.9% during the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares during the last quarter. Romano Brothers AND Company boosted its stake in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after purchasing an additional 102 shares during the period. Finally, Financial Advocates Investment Management grew its holdings in Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 103 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.